Cargando…

Genetic Background May Contribute to PAM50 Gene Expression Breast Cancer Subtype Assignments

Recent advances in genome wide transcriptional analysis have provided greater insights into the etiology and heterogeneity of breast cancer. Molecular signatures have been developed that stratify the conventional estrogen receptor positive or negative categories into subtypes that are associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ying, Bai, Ling, Geiger, Thomas, Goldberger, Natalie, Walker, Renard C., Green, Jeffery E., Wakefield, Lalage M., Hunter, Kent W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756056/ https://www.ncbi.nlm.nih.gov/pubmed/24015230 http://dx.doi.org/10.1371/journal.pone.0072287

Ejemplares similares

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression
por: Kwan, Marilyn L, et al.
Publicado: (2015)

Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
por: Ochoa, Soledad, et al.
Publicado: (2020)

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
por: Veerla, Srinivas, et al.
Publicado: (2023)

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
por: Bastien, Roy RL, et al.
Publicado: (2012)

Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes
por: Liu, Rong, et al.
Publicado: (2016)

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012)

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
por: Lundgren, Christine, et al.
Publicado: (2022)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay
por: Hurson, Amber N., et al.
Publicado: (2023)

PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications
por: Jørgensen, Charlotte Levin Tykjær, et al.
Publicado: (2021)

Radiogenomics analysis reveals the associations of dynamic contrast-enhanced–MRI features with gene expression characteristics, PAM50 subtypes, and prognosis of breast cancer
por: Ming, Wenlong, et al.
Publicado: (2022)

An integrated systems genetics screen reveals the transcriptional structure of inherited predisposition to metastatic disease
por: Faraji, Farhoud, et al.
Publicado: (2014)

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
por: Kim, Hee Kyung, et al.
Publicado: (2019)

Research-based PAM50 signature and long-term breast cancer survival
por: Pu, Minya, et al.
Publicado: (2019)

A comparative study of PCS and PAM50 prostate cancer classification schemes
por: Yoon, Junhee, et al.
Publicado: (2021)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B
por: Raj-Kumar, Praveen-Kumar, et al.
Publicado: (2019)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015)

Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes
por: Mathews, James C., et al.
Publicado: (2019)

Functional Analysis of Prognostic Gene Expression Network Genes in Metastatic Breast Cancer Models
por: Geiger, Thomas R., et al.
Publicado: (2014)

PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
por: Phakathi, Boitumelo, et al.
Publicado: (2023)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
por: Lien, Tonje G., et al.
Publicado: (2021)

Comprehensive analysis based on DNA methylation and RNA-seq reveals hypermethylation of the up-regulated WT1 gene with potential mechanisms in PAM50 subtypes of breast cancer
por: Ren, Chongyang, et al.
Publicado: (2021)

On the group theoretical background of assigning stepwise mutations onto phylogenies
por: Fischer, Mareike, et al.
Publicado: (2012)

The LEPSIS Pam-File
por: DELPHI Collaboration
Publicado: (1982)

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis
por: Yang, Yuan, et al.
Publicado: (2017)

Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome()()
por: Siegfried, Jill M., et al.
Publicado: (2015)

Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
por: Erber, Ramona, et al.
Publicado: (2022)

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Modifications to the LEPSIM Pam-File
por: DELPHI Collaboration
Publicado: (1982)

El Pim-pam-pum
por: Ionesco, Eugène

The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience
por: Dank, Magdolna, et al.
Publicado: (2023)

Comparative Analysis of Putative Orthologues of Mitochondrial Import Motor Subunit: Pam18 and Pam16 in Plants
por: Chen, Xuejin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_llpleo87bihrhua6ij5oi725to